Background Erlotinib (Tarceva, OSI Pharmaceuticals, Melville, NY) is an oral, epidermal
growth factor receptor tyrosine kinase inhibitor that has antitumor activity and good …

Introduction The aim of this study was to evaluate the efficacy and safety of Erlotinib in
Japanese patients with previously treated non-small cell lung cancer (NSCLC). Available …

Objective This study is to analyze the data of Chinese subpopulation in the Tarceva Lung
Cancer Survival Treatment Study (TRUST-China) which was a global Phase IV study …

Background: Erlotinib is a selective epidermal growth factor receptor tyrosine kinase
inhibitor (EGFR-TKI). We conducted two phase II studies (JO16565 and JO18396) of …

Introduction: Erlotinib is a small molecule inhibitor of epidermal growth factor receptor
tyrosine-kinase activity that has been shown to significantly increase survival for patients …

Erlotinib is a highly potent inhibitor of epidermal growth factor receptor tyrosine-kinase
activity that significantly prolongs overall survival in patients with non-small-cell lung cancer …

Erlotinib is a potent reversible HER1/epidermal growth factor receptor tyrosine kinase
inhibitor with single-agent activity in patients with non-small cell lung cancer. The aim of this …

Background: Treatment of non-small cell lung cancer (NSCLC) with tyrosine kinase
inhibitors (TKIs) of epidermal growth factor receptor (EGFR) and particularly erlotinib …

Introduction: Erlotinib is an epidermal growth factor receptor tyrosine kinase inhibitor that
significantly increases survival for patients with previously treated advanced non-small cell …

The aim of this study was to evaluate the efficacy and safety of erlotinib, an epidermal growth
factor receptor tyrosine kinase inhibitor, in Japanese patients with relapsed or recurrent …